David A. Cheresh

Q: What Schools Are Affiliated With David A. Cheresh

David A. Cheresh is affiliated with the following schools: University of California, San Diego, Purdue University, University of Toronto, University of Washington, University of Illinois Chicago

David A. Cheresh's AcademicInfluence.com Rankings

David A. Cheresh

Biology

#2875

World Rank

#4489

Historical Rank

Cell Biology

#85

World Rank

#90

Historical Rank

biology Degrees

Download Badge

Biology

Why Is David A. Cheresh Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David Cheresh is a Michigan-born scientist who studies angiogenesis and cancer metastasis. His early research focused on the function of integrins, cellular receptors for the extracellular matrix, in cell migration and survival. His current work is on signaling aspects of cell invasion by vascular cells and tumor cells, with a focus on preventing tumor metastasis.

(See a Problem?)

David A. Cheresh's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Requirement of vascular integrin alpha v beta 3 for angiogenesis. (1994) (2874)
Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment (1993) (2234)
Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels (1994) (2185)
Integrins in cancer: biological implications and therapeutic opportunities (2010) (1980)
Role of integrins in cell invasion and migration (2002) (1752)
Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 (1996) (1529)
Tumor angiogenesis: molecular pathways and therapeutic targets (2011) (1508)
Regulation of Cell Motility by Mitogen-activated Protein Kinase (1997) (1317)
Definition of Two Angiogenic Pathways by Distinct αv Integrins (1995) (1272)
Integrins in cancer: biological implications and therapeutic opportunities (2010) (1269)
Tumor Regression by Targeted Gene Delivery to the Neovasculature (2002) (834)
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. (1995) (832)
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. (1994) (831)
Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. (1999) (811)
Pathophysiological consequences of VEGF-induced vascular permeability (2005) (807)
Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. (1996) (697)
CAS/Crk Coupling Serves as a “Molecular Switch” for Induction of Cell Migration (1998) (692)
The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. (1999) (664)
Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity (1998) (649)
Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging (1998) (627)
Get a ligand, get a life: integrins, signaling and cell survival (2002) (608)
Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. (1987) (585)
Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins (2001) (576)
Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. (2015) (567)
Differential regulation of cell motility and invasion by FAK (2003) (565)
The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. (1995) (562)
Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. (1987) (537)
Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. (1993) (533)
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. (2012) (513)
MicroRNA-132–mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis (2010) (509)
A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation (2008) (497)
Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis (2004) (479)
Definition of two angiogenic pathways by distinct alpha v integrins. (1995) (465)
Deletion of Vascular Endothelial Growth Factor in myeloid cells accelerates tumorigenesis (2008) (453)
Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. (1996) (441)
Vitronectin and its receptors. (1993) (433)
Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization (1994) (428)
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis (2008) (427)
Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. (1994) (424)
Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. (1991) (424)
Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis (1998) (411)
Integrins and cancer. (1996) (391)
Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. (1991) (389)
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. (2000) (385)
Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms (1993) (382)
Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. (1996) (381)
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. (1984) (363)
Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. (2004) (354)
Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. (1992) (351)
Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. (1998) (344)
Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin (2007) (343)
Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. (2011) (342)
Tyrosine Phosphorylation of VE-cadherin Prevents Binding of p120- and β-Catenin and Maintains the Cellular Mesenchymal State* (2005) (336)
Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli (2003) (335)
Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke (2001) (333)
Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells (1989) (329)
Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signaling (2002) (329)
Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface (1991) (324)
Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin (2009) (323)
αvβ3 and αvβ5 Integrin Expression in Glioma Periphery (2001) (312)
A novel vitronectin receptor integrin (α v β x ) is responsible for distinct adhesive properties of carcinoma cells (1989) (311)
Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist (1999) (311)
An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition (2014) (307)
Adhesion events in angiogenesis. (2001) (300)
An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. (1995) (296)
Integrins and angiogenesis. (2004) (295)
Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. (1998) (291)
VEGF-induced vascular permeability is mediated by FAK. (2012) (290)
Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins (1986) (290)
Receptor tyrosine kinase signaling required for integrin alpha v beta 5- directed cell motility but not adhesion on vitronectin (1994) (281)
Differential αv integrin–mediated Ras-ERK signaling during two pathways of angiogenesis (2003) (271)
αV integrins in angiogenesis and cancer. (2011) (271)
Regulation of Cell Contraction and Membrane Ruffling by Distinct Signals in Migratory Cells (1999) (270)
Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist (2001) (270)
Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. (2001) (268)
Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen (1992) (262)
Cell adhesion and angiogenesis. (1996) (259)
A human aminoacyl-tRNA synthetase as a regulator of angiogenesis (2002) (258)
Requirement of Receptor-bound Urokinase-type Plasminogen Activator for Integrin αvβ5-directed Cell Migration* (1996) (243)
Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3 (1996) (237)
An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2 (1987) (235)
The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin (1990) (234)
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. (1987) (232)
Induction of the Angiogenic Phenotype by Hox D3 (1997) (228)
O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. (1984) (224)
Integrin αVβ3 Promotes M21 Melanoma Growth in Human Skin by Regulating Tumor Cell Survival (1999) (221)
The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit. (1988) (218)
Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. (1990) (214)
Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo (1995) (214)
Transient functional expression of alphaVbeta 3 on vascular cells during wound repair. (1996) (211)
Integrin αvβ1 Is an Adenovirus Coreceptor (2001) (204)
Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-OH kinase. (1998) (203)
Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. (2008) (198)
ECM Remodeling Regulates Angiogenesis: Endothelial Integrins Look for New Ligands (2002) (197)
Protein kinase C regulates alpha v beta 5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation (1996) (196)
Integrins, angiogenesis and vascular cell survival. (1996) (195)
Integrin αvβ3/c-src “Oncogenic Unit” Promotes Anchorage-independence and Tumor Progression (2009) (195)
A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. (1984) (194)
FRNK blocks v‐Src‐stimulated invasion and experimental metastases without effects on cell motility or growth (2002) (193)
Role of alpha v integrins during angiogenesis. (2000) (183)
Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. (1984) (183)
Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. (1997) (182)
Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. (2001) (179)
Cell-type Specific Recognition of RGD- and Non-RGD-containing Cell Binding Domains in Fibrillin-1 (*) (1996) (179)
RGD-dependent linkage between plant cell wall and plasma membrane: consequences for growth (1989) (170)
Integrin (alpha v beta 3)-ligand interaction. Identification of a heterodimeric RGD binding site on the vitronectin receptor. (1990) (166)
Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. (1992) (165)
Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors (2006) (162)
Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy (2019) (159)
Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. (1989) (158)
A fragment of human TrpRS as a potent antagonist of ocular angiogenesis (2002) (156)
URE 3 ] as an Altered URE 2 Protein : Evidence for a Prion Analog in Saccharomyces cerevisiae (155)
Specific roles of the αVβ1, αVβ3 and αVβ5 integrins in avian neural crest cell adhesion and migration on vitronectin (1994) (154)
Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. (2000) (154)
Mechanisms and Consequences of Affinity Modulation of Integrin αVβ3 Detected with a Novel Patch-engineered Monovalent Ligand* (1999) (153)
Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK (2008) (151)
Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. (1995) (148)
Integrin CD11b activation drives anti-tumor innate immunity (2018) (145)
An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization (1995) (136)
Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. (1999) (136)
A Single Immunoglobulin-like Domain of the Human Neural Cell Adhesion Molecule L1 Supports Adhesion by Multiple Vascular and Platelet Integrins (1997) (136)
Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function (2014) (135)
Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. (2009) (134)
Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. (1987) (131)
A Dominant-Negative p65 PAK Peptide Inhibits Angiogenesis (2002) (131)
Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. (2010) (128)
Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. (1995) (127)
Arg-Gly-Asp recognition by a cell adhesion receptor requires its 130-kDa alpha subunit. (1987) (127)
Review: The Integrin αvβ3: Angiogenesis and Apoptosis (1995) (126)
Regulation of angiogenesis: apoptotic cues from the ECM (2008) (125)
Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. (1999) (123)
Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. (2001) (121)
Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. (2012) (121)
Integrin α4β1 signaling is required for lymphangiogenesis and tumor metastasis (Cancer Research (2010) 70, (3042-51) DOI (2010) (121)
Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel (1991) (119)
Induction of Angiogenesis by a Fragment of Human Tyrosyl-tRNA Synthetase* (2002) (118)
Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. (1990) (114)
The Vitronectin Receptor vfl3 Binds Fibronectin and Acts in Concert with asfll in Promoting Cellular Attachment and Spreading on Fibronectin (1990) (114)
Integrin alphavbeta3 is expressed in selected microvessels after focal cerebral ischemia. (1996) (113)
Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. (1989) (111)
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. (2008) (111)
Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. (1999) (111)
Adenovirus Endocytosis via αvIntegrins Requires Phosphoinositide-3-OH Kinase (1998) (110)
Aerosolized Phosphoinositide 3-Kinase γ/δ Inhibitor TG100-115 [3-[2,4-Diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a Therapeutic Candidate for Asthma and Chronic Obstructive Pulmonary Disease (2009) (109)
The Role of αv Integrins during Angiogenesis (1998) (107)
Human tumor antigens. (1987) (107)
Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. (1996) (104)
Phosphoinositide 3-kinase γ/δ inhibition limits infarct size after myocardial ischemia/reperfusion injury (2006) (103)
Integrin txv/35 Selectively Promotes Adenovirus Mediated Cell Membrane Permeabilization (1994) (103)
Use of the 10-day-old chick embryo model for studying angiogenesis. (1999) (103)
Adhesive properties of the beta 3 integrins: comparison of GP IIb-IIIa and the vitronectin receptor individually expressed in human melanoma cells (1991) (102)
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. (2017) (102)
A role for VEGF as a negative regulator of pericyte function and vessel maturation. (2008) (99)
Regulation of Adenovirus Membrane Penetration by the Cytoplasmic Tail of Integrin β5 (2000) (98)
Integrin alpha(v)beta1 is an adenovirus coreceptor. (2001) (97)
Induction of carcinoma cell migration on vitronectin by NF-kappa B-dependent gene expression. (1995) (96)
Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. (1985) (95)
Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. (1986) (94)
Disialoganglioside GD2 distributes preferentially into substrate- associated microprocesses on human melanoma cells during their attachment to fibronectin (1986) (92)
Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression (2012) (92)
Arginine-glycine-aspartic acid binding leading to molecular stabilization between integrin alpha v beta 3 and its ligand. (1991) (91)
A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. (1998) (88)
Formation of endothelial lumens requires a coordinated PKCϵ-, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation (2009) (85)
Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. (1996) (84)
Interaction of an acute phase reactant, alpha 1-acid glycoprotein (orosomucoid), with the lymphoid cell surface: a model for non-specific immune suppression. (1984) (84)
Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. (1991) (83)
Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin αvβ5 Axis. (2019) (82)
Integrins : molecular and biological responses to the extracellular matrix (1994) (82)
Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. (1992) (80)
cDNA sequence of the human integrin beta 5 subunit. (1990) (80)
Identification of a novel integrin beta subunit expressed on cultured monocytes (macrophages). Evidence that one alpha subunit can associate with multiple beta subunits. (1990) (79)
Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. (2007) (76)
Extracellular matrix and integrin composition of the normal bladder wall (2004) (75)
Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3. (1986) (74)
Targeted Nanogels: A Versatile Platform for Drug Delivery to Tumors (2011) (73)
Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia (2011) (72)
VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy (2009) (72)
Receptor Tyrosine Kinase Signaling Required for Integrin c v/35-directed Cell Motility but Not Adhesion on Vitronectin (1994) (71)
Integrin 4383 rescues melanoma cells from apoptosis in three-dimensional dermal collagen (69)
Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. (2014) (68)
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. (2017) (67)
RBBP9: A tumor-associated serine hydrolase activity required for pancreatic neoplasia (2009) (67)
PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes (2013) (67)
Oncogenic Ras/Src cooperativity in pancreatic neoplasia (2011) (66)
Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. (2011) (66)
Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. (2006) (66)
Cooperation between VEGF and beta3 integrin during cardiac vascular development. (2007) (65)
Integrins: Structure, Function, and Biological Properties (1993) (64)
MicroRNA-mediated regulation of the angiogenic switch (2011) (64)
Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand. (1999) (63)
A MEK-independent role for CRAF in mitosis and tumor progression (2011) (61)
The role of alphav integrins during angiogenesis. (1998) (59)
Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting. (2013) (58)
Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin alpha(V)beta(3). (2001) (58)
H-Ras Regulates Angiogenesis and Vascular Permeability by Activation of Distinct Downstream Effectors (2008) (57)
Recent advances in cell adhesion molecules and extracellular matrix proteins: potential clinical implications (1997) (57)
REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis. (1995) (56)
Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRβ/B-RAF (2010) (56)
Adenovirus entry into host cells: a role for αv integrins (1994) (56)
Structural and biologic properties of integrin-mediated cell adhesion. (1992) (56)
A critical role for Lyn kinase in strengthening endothelial integrity and barrier function. (2013) (55)
A beta turn in the cytoplasmic tail of the integrin alpha v subunit influences conformation and ligand binding of alpha v beta 3. (1994) (55)
A novel vitronectin receptor integrin (alpha v beta x) is responsible for distinct adhesive properties of carcinoma cells. (1989) (55)
Suppression of p53 Activity and p21 WAF1/CIP1 Expression by Vascular Cell Integrin during Angiogenesis (1996) (55)
Specific roles of the alpha V beta 1, alpha V beta 3 and alpha V beta 5 integrins in avian neural crest cell adhesion and migration on vitronectin. (1994) (55)
Matrix Valency Regulates Integrin-mediated Lymphoid Adhesion via Syk Kinase (1999) (55)
Design, synthesis and biological evaluation of nonpeptide integrin antagonists. (1998) (54)
MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment (2016) (54)
Potentiation of Cell Migration by Adhesion-dependent Cooperative Signals from the GTPase Rac and Raf Kinase* (1999) (53)
The RON‐receptor regulates pancreatic cancer cell migration through phosphorylation‐dependent breakdown of the hemidesmosome (2012) (50)
Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study. (2008) (49)
Bifurcation of Cell Migratory and Proliferative Signaling by the Adaptor Protein Shc (1999) (49)
Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin alpha v-subunit. (1996) (46)
Labeling of integrin alpha v beta 3 with 58Co(III). Evidence of metal ion coordination sphere involvement in ligand binding. (1991) (45)
αvβ3 and αvβ5 Integrin expression in meningiomas (2000) (44)
Engagement of the Osteoclast Integrin αvβ3 by Osteopontin Stimulates Phosphatidylinositol 3‐Hydroxyl Kinase Activity ab (1995) (43)
Emerging Role of Micro-RNAs in the Regulation of Angiogenesis. (2011) (42)
Structure, function and biological properties of integrin αvβ3on human melanoma cells (1991) (41)
β1 integrin antagonism on adherent, differentiated human neuroblastoma cells triggers an apoptotic signaling pathway (2000) (41)
EGFR-dependent pancreatic carcinoma cell metastasis via Rap1 activation (2011) (41)
Cell growth and matrix invasion of EBV-immortalized human B lymphocytes is regulated by expression of αv integrins (2000) (39)
Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis (2017) (38)
Kinase-independent role for CRAF-driving tumour radioresistance via CHK2 (2015) (37)
A role for angiogenesis in rheumatoid arthritis. (1999) (37)
Regulation of cell migration by the integrin beta subunit ectodomain. (1996) (37)
Reduced Intimal Thickening Following αvβ 3 Blockade is Associated with Smooth Muscle Cell Apoptosis (1998) (37)
a v b 3 during Angiogenesis (1996) (36)
Death to a blood vessel, death to a tumor (1998) (35)
EGFR-Mediated Carcinoma Cell Metastasis Mediated by Integrin αvβ5 Depends on Activation of c-Src and Cleavage of MUC1 (2012) (35)
Integrins in thrombosis, wound healing and cancer. (1991) (34)
Gain-of-function mutational activation of human tRNA synthetase procytokine. (2007) (34)
Loss of p53 Compensates for αv-Integrin Function in Retinal Neovascularization* (2002) (32)
Agonizing integrin antagonists? (2009) (30)
Role of alpha V integrins and vitronectin in human melanoma cell growth. (1992) (29)
Characterization of a membrane surface glycoprotein associated with T-cell activation. (1985) (28)
Localization of beta 1, beta 3, alpha 5, alpha v, and alpha IIb subunits of the integrin family in spreading human erythroleukemia cells. (1990) (28)
Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. (2004) (26)
Robo4 counteracts VEGF signaling (2008) (26)
Cell adhesion mechanisms and their potential impact on wound healing and tumor control. (1990) (25)
Cell growth and matrix invasion of EBV-immortalized human B lymphocytes is regulated by expression of alpha(v) integrins. (2000) (24)
Glioblastomas require integrin αvβ3/PAK4 signaling to escape senescence. (2015) (24)
Antiintegrin av,83 blocks human breast cancer growth and angiogenesis in human skin (2013) (23)
Alpha(v)beta3 and alpha(v)beta5 integrin expression in meningiomas. (2000) (22)
Building a better Trap (2003) (21)
Augmentation of lymphocyte responses by monoclonal antibodies to the gangliosides GD3 and GD2: the role of protein kinase C, cyclic nucleotides, and intracellular calcium. (1989) (21)
Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. (1990) (20)
Binding of osteopontin to the osteoclast integrin αvβ3 (2005) (20)
Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. (1991) (20)
Human tumour-associated antigens: targets for monoclonal antibody-mediated cancer therapy. (1985) (19)
Recognition of Osteopontin and Related Peptides by an aVe3 Integrin Stimulates Immediate Cell Signals in Osteoclasts* (2001) (18)
hESC Differentiation toward an Autonomic Neuronal Cell Fate Depends on Distinct Cues from the Co-Patterning Vasculature (2015) (18)
Selective type IV collagen defects in the urothelial basement membrane in interstitial cystitis. (1995) (18)
Herpesvirus hijacks an integrin (2002) (17)
Blood leukocytes bind platelet glycoprotein (IIb-IIIa)' but do not express the vitronectin receptor. (1990) (16)
Targeted delivery of mutant Raf kinase to neovessels causes tumor regression. (2002) (16)
Pseudopodium-enriched atypical kinase 1 mediates angiogenesis by modulating GATA2-dependent VEGFR2 transcription (2018) (15)
Adenovirus entry into host cells: a role for alpha(v) integrins. (1994) (15)
Binding of osteopontin to the osteoclast integrin alpha v beta 3. (1993) (15)
Suppressing NFAT increases VEGF signaling in hemangiomas. (2008) (15)
A wake-up call for hibernating tumour cells (2013) (15)
Arming tumor-associated macrophages to reverse epithelial cancer progression. (2019) (15)
Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke’s encephalopathy (2017) (15)
A link between integrins and MMPs in angiogenesis (1999) (14)
Anti‐Glycosphingolipid autoantibodies in rheumatologic disorders (1994) (14)
avb3 and avb5 Integrin Expression in Glioma Periphery (2001) (14)
A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels (2011) (13)
Integrins in Angiogenesis (2008) (13)
Structural and functional properties of ganglioside antigens on human tumors of neuroectodermal origin. (1985) (13)
Mitogen-induced blastogenesis and receptor mobility inhibition by breast cancer serum with elevated orosomucoid (alpha 1-acid glycoprotein) levels. (1982) (12)
Human Melanoma Cells Derived from Lymphatic Metastases Use Integrin aCv3 to Adhere to Lymph Node Vitronectin (2013) (12)
Extended-working-distance multiphoton micromanipulation microscope for deep-penetration imaging in live mice and tissue. (2009) (12)
Ganglioside Involvement in Tumor Cell—Substratum Interactions (1987) (11)
Matrix metalloproteinase/integrin interactions as target for anti-angiogenic treatment strategies. (2002) (11)
Minireviews The Role of av Integrins during Angiogenesis (10)
Adhesive Properties of the/ 3 Integrins: Comparison of GP IIb-IIIa and the Vitronectin Receptor Individually Expressed in Human Melanoma Cells (2002) (9)
Abstract 1916: β3 integrin/KRAS/RalB complex drives tumor stemness and resistance to EGFR inhibition (2014) (8)
Variety in the tumor microenvironment: integrin splicing regulates stemness. (2014) (8)
Regulation of cell migration by the integrin β subunit ectodomain (1996) (8)
Reduced intimal thickening following alpha(v)beta3 blockade is associated with smooth muscle cell apoptosis. (1998) (8)
NompC TRP Channel Required for Vertebrate Sensory Hair Cell Mechanotransduction (2003) (7)
Human melanoma cell attachment involves an Arg-Gly-Asp-directed adhesion receptor and the disialoganglioside GD2. (1989) (6)
GLIOBLASTOMA CELLS SYNTHESIZE AND SECRETE THE ADHESIVE PROTEIN VITRONECTIN: 235 (1990) (5)
Enzymatic basis for increased expression of GD3 on human melanoma cells derived from metastatic lesions (1988) (5)
Emerging Role of MicroRNAs in the Regulation of Angiogenesis (2012) (5)
Focal adhesion kinase (FAK) activity promotes tumor growth and neo-vascularization via upregulation of angiogenic factors (2005) (4)
Potentiation of interleukin-2 production and its binding by monoclonal antibodies to the gangliosides GD3 and GD2 (2004) (4)
Detection of Ganglioside GD 2 in Tumor Tissues and Sera of Neuroblastoma Patients 1 (2006) (4)
Compensatory role for proline-rich tyrosine kinase 2 (Pyk2) during angiogenesis in adult mice lacking endothelial cell focal adhesion kinase (FAK) (2008) (4)
Abstract 3841: An integrin αvβ3/c-Src oncogenic unit promotes anchorage independence and tumor progression (2010) (4)
Tumor angiogenesis: putting a value on plastic GEMMs. (2014) (4)
Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation (2023) (3)
Disialoganglioside GD 2 on Human Neuroblastoma Cells : Target Antigen for Monoclonal Antibody-mediated Cytolysis and Suppression of Tumor Growth 1 (2006) (3)
Targeting the Achilles’ heel of drug-resistant cancer stem cells (2014) (3)
Cancer forum (1992) (3)
Derivation of vasculature from embryonic stem cells. (2010) (3)
2 Integrins and proteases in angiogenesis and disease (1997) (3)
In&grins aJSQ and U& Promote Adenovirus Internalization but Not Virus Attachment (1993) (3)
Re-thinking the preclinical development of GBM therapeutics (2018) (2)
Disialoganglioside GD 3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis ( melanoma ganglioside antigen / cytolysis / immunotherapy ) (2003) (2)
Book Review Antiangiogenic Cancer Therapy Edited by Darren W. Davis, Roy S. Herbst, and James L. Abbruzzese. 841 pp., illustrated. Boca Raton, FL, CRC Press, 2008. $199.95. 978-0-8493-2799-5 (2008) (2)
Angiogenesis : in vitro systems (2008) (2)
Differential (cid:2) v integrin–mediated Ras-ERK signaling during two pathways of angiogenesis (2003) (2)
Protein Kinase Activity during Angiogenesis (1998) (2)
Blocked herpes simplex virus type 2-specific DNA synthesis in simian virus 40-transformed hamster cells permissive for herpes simplex virus type 1 (1983) (2)
Methods and compositions for inhibition of angiogenesis (1995) (2)
Principal investigators weigh in (2010) (1)
The Role of Integrin αvβ3 in Cell Survival and Angiogenesis (1997) (1)
Loss of endothelial Focal adhesion kinase in mice causes lung vascular leak, alveolar destruction and inflammation (2010) (1)
Methods and compositions for inhibiting angiogenesis (1995) (1)
Getting unglued about integrins. The Molecular Basis of Cellular Adhesion: A UCLA symposium, sponsored by Genentech and Glaxo Steamboat Springs, CO, USA, January 20-26, 1990. (1990) (1)
Abstract SY27-04: Induction of cancer stemness and drug resistance by EGFR blockade (2015) (1)
Integrin a v b 1 Is an Adenovirus Coreceptor † (2001) (1)
Glut3 addiction is a druggable vulnerability for a molecularly defined subpopulation of glioblastoma. (2017) (1)
VEGF-Induced Cytoskeletal Alterations Relating to Vascular Permeability in Endothelial Cells (2002) (1)
BIOCHEMICAL AND FUNCTIONAL PROFILES OF TWO UNIQUE MELANOMA ASSOCIATED ANTIGENS (1985) (1)
A structural basis for bidirectional integrin signalling. (1994) (1)
The Biological Function of β3 Integrins and Other Vitronectin Receptors (1994) (1)
avb3 and avb5 Integrin Expression in Meningiomas (2000) (1)
Abstract 2192: Stress-induced reprogramming of epithelial cancers toward a stem-like fate (2015) (1)
A Model For Alpha-1-Acid Glycoprotein-Mediated Immunosuppression In The Metastatic Breast Cancer Patient: Effects On The Lymphoid Cell Surface (1982) (1)
Abstract 18: MicroRNA-103 induces DNA damage and radiosensitizes the tumor vasculature (2014) (1)
Maximizing differences in the concanavalin A-induced blastogenic responses of lymphocytes from breast cancer patients and controls by the use of alpha-methyl-D-mannoside. (1982) (1)
Structure, Function, and Biosynthesis of Ganglioside Antigens Associated with Human Tumors Derived From the Neuroectoderm (1987) (1)
Tumor progression induced by integrin αvβ3 mediated anchorage‐dependent and ‐independent signaling (79.3) (2014) (1)
Integrins alpha(v)beta(3) and alpha(v)beta(5) are selectively expressed in active human retinal and choroidal neovascular membranes (1996) (0)
ANGI-09. microRNA INHIBITION OF ENDOTHELIAL DNA REPAIR CAPACITY AS A GLIOBLASTOMA THERAPEUTIC STRATEGY (2016) (0)
Joint British Association and Irish Association Cancer Research Meeting. Dublin, Ireland, 21-24 June 1998. Abstracts. (1998) (0)
A human aminoacyl-tRNA syl of angiogenesis (2016) (0)
Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy (2019) (0)
Abstract C78: Integrin αvβ3 drives stemness in the pregnant and neoplastic mammary gland (2013) (0)
VEGFasaninhibitoroftumor vesselmaturation:implicationsfor cancertherapy (2009) (0)
Abstract 389: Mice with kinase-dead FAK mutation in endothelial cells are protected from VEGF-induced permeability and are resistant to tumor cell metastasis (2010) (0)
Angiogenesis : in vivo systems (2008) (0)
Issue Information (1994) (0)
Abstract 4740: Selective ablation of metastatic disease with integrin ανβ3 targeted nanoparticle drug delivery (2008) (0)
&agr;v&bgr;3 and &agr;v&bgr;5 Integrin Expression in Meningiomas (2000) (0)
Abstract 5202: MUC1 oncogene is required for EGF/Src-driven carcinoma cell metastasis (2010) (0)
Procedure and useful compositions for inhibition of angiogenesis. (1995) (0)
GLAUCOMA, MACULAR DEGENERATION AND CAPLLARY PROLIFERATION WITH ALPHAVBETA3-SPECIFIC ANTIBODES FOREIGN PATENT DOCUMENTS (2017) (0)
Abstract LB-049: Cancer stem cell-produced lysophosphatidic acid reprograms surrounding tumor cells to a stem-like state (2018) (0)
Comprar Angiogenesis: In Vivo Systems, Part B Volume 445 | David. A Cheresh | 9780123743145 | Academic Press (2009) (0)
Plat el et Vitro nec t in Receptor Exp res s ion Differentiates Iraqi - Jewi s h From Arab Patients With Glanzmann Thrombasthenia in Israel (2003) (0)
Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. (1995) (0)
DISTINCT GLIOBLASTOMA CELL LOCALIZATION OF INTEGRINS αvβ3 AND αvβ5 (1993) (0)
MicroRNA Regulation of the Pathological Angiogenic Response (2011) (0)
A novel xenograft model of gastrointestinal stromal tumors. (2012) (0)
Pseudopodium-enriched atypical kinase 1 mediates angiogenesis by modulating GATA2-dependent VEGFR2 transcription (2018) (0)
Award Number: W81XWH-04-1-0120 TITLE: The Role of I-kappa-B Kinases in Prostate Carcinogenesis and the Effect of Their Inhibition on Survival of Prostate Tumors (2007) (0)
Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity. (1998) (0)
Abstract 1474: Semaphorin 3A potentiates metastatic disease by binding to endothelial Neuropilin-1 and disrupting vascular barrier function (2011) (0)
Abstract 3067: Galectin-3, a target for KRAS-addicted lung cancer (2017) (0)
Vascular Dependence of Neuronal Fate Determination (2008) (0)
1 Is an Adenovirus Coreceptor β v α Integrin (2014) (0)
Abstract 3966: Targeting integrin αvβ3-expressing cancer stem cells to manipulate tumor-associated macrophages (2017) (0)
Abstract B39: Inhibiting endothelial FAK activity blocks tumor cell extravasation (2013) (0)
The αv Integrins (2017) (0)
Preventing pathological angiogenesis in the retina using a microRNA that regulates endothelial cell survival (2016) (0)
Integrin CD11b activation drives anti-tumor innate immunity (2018) (0)
Abstract LB-493: Blocking the integrin αvβ3-CRAF axis with Cilengitide arrests glioblastoma cells in pro-metaphase (2012) (0)
Abstract 2919: Unexpected role of CRAF in tumor cell mitosis revealed by an allosteric inhibitor (2011) (0)
Process for the modulation of angiogenesis by the tyrosine kinase src (1999) (0)
kinase regulates expression. (2012) (0)
Preface: a tribute to Dr. Judah Folkman. (2008) (0)
Serum α-1-glycoprotein enhancement of concanavalin A receptor crosslinking and inhibition of Con A induced blastogenesis (1981) (0)
Combined targeting of VEGF and PDGF to reverse neovascularization and prevent fibrosis (2015) (0)
Integrin-Targeted angiostatics (2002) (0)
Abstract A04: Endothelial FAK activity controls vascular permeability and tumor metastasis (2015) (0)
Procedes et compositions inhibant l'angiogenese (1997) (0)
Suitable methods and compositions for inhibiting angiogenesis (1995) (0)
Electrical Engineering (Electronic Circuits and Systems) (2010) (0)
Molecular and biological profiles of two unique antigens associated with human melanoma (1985) (0)
Abstract SY16-02: microRNA regulation of the tumor angiogenic switch (2011) (0)
The methods and compositions which are useful in inhibiting angiogenesis (1996) (0)
VASCULAR BIOLOGY A critical role for Lyn kinase in strengthening endothelial integrity and barrier function (2013) (0)
&agr;v&bgr;3 and &agr;v&bgr;5 Integrin Expression in Glioma Periphery (2001) (0)
Microrna-132 Antagonism Potently Limits Neovascularization In Multiple Disease Models (2012) (0)
Tissue Window Chamber System for Validation and Optimization of Dynamic Contrast Enhanced Tumor Imaging (2008) (0)
Structure of c-Kit with allosteric inhibitor 3G8 (2019) (0)
Metastasis is a highly stressful process (2020) (0)
Specific sialyltransferase is responsible for the synthesis of GD/sup 3/, a ganglioside preferentially expressed on human metastatic melanoma cells (1986) (0)
Abstract A036: Integrin αvβ3 drives the mammary stem cell state during pregnancy (2013) (0)
Src kinase inhibition reduces laser or VEGF induced retinal vascular permeability (2004) (0)
Monographs editor. (2011) (0)
Methods and composition for inhibition of angiogenesis (1995) (0)
Title Compensatory role for Pyk 2 during angiogenesis in adult mice lacking endothelial cell (2008) (0)
Ralph A. Reisfeld, PhD: In Memoriam (1926–2020) (2021) (0)
Rational design and physiological selection of a RAF pathway inhibitor that disrupts angiogenesis and tumor growth (2008) (0)
Glioma and Medulloblastoma Growth Inhibition by αV Integrin Antagonist (1999) (0)
Abstract P076: Humanized anti-αvβ3 antibody engineered to selectively promote macrophage-mediated cancer cell death (2022) (0)
3 mediated angiogenesis inhibitor (1997) (0)
Abstract 113: c-Kit-dependent tissue resident macrophage progenitors drive cancer progression (2019) (0)
Endothelial FAK activity controls vascular permeability and tumor metastasis (2015) (0)
Pharmaceutical compositions comprising the Src and / or Yes, and the use thereof (2000) (0)
Integrin-Mediated Signaling Events Involved in Adenovirus Internalization and Cell Motility (2010) (0)
71. Plectin Binds the RON Receptor Kinase and is Required for Ligand-Dependent Migration in Pancreatic Cancer Cells (2009) (0)
Abstract LB-344: Emergence of carcinoma resistance to EGFR blockade via an integrin avb3/RalB/NFkB signaling axis (2012) (0)
Procedures for treating tumors and metastases using a combination of therapies and immunotherapies Antiangiogenic. (2000) (0)
Methods and compositions useful in inhibiting angiogenesis (1995) (0)
Useful methods for modulating angiogenesis by the use of tyrosine kinase SRC (1999) (0)
Identification of putative apoptomiRs that prevent endothelial cell proliferation (2015) (0)
PROCEDURES useful for modulating angiogenesis USING TYROSINE KINASE Src. (1999) (0)
Abstract 4240: Targeting Galectin-3 to reverse tumor stemness and drug resistance (2014) (0)

This paper list is powered by the following services:

Other Resources About David A. Cheresh

en.wikipedia.org

What Schools Are Affiliated With David A. Cheresh?

David A. Cheresh is affiliated with the following schools: